View Challenges

Displaying 1 - 10 of 28
In progress
2017
To develop an in silico-based tool that reliably predicts human respiratory irritancy potential of chemicals.
In progress
2017
To establish improved and increased throughput methods and approaches to better account for bioavailability through development of dosing and measurement strategies of test chemicals in in vitro assays. 
In progress
2017
To develop a data model that integrates and maps information on the relation between specific genes and specific physiology, or specific compounds and specific effects, between non-mammalian and mammalian...
In progress
2016
To develop reliable predictions which confidently classify mixtures of chemicals for acute oral toxicity, skin and eye irritation with a focus on relevance for human safety. These should fulfil acute GHS...
In progress
2016
The overall aim of the EASE CRACK IT Challenge is to generate an approach that improves the implantation rates of early stage embryos when combined with extended in vitro culture and non-surgical embryo...
In progress
2016
To establish a 3D retinal cell model which is physiologically-competent and predictive of human physiology for use in the development of new ophthalmology treatments.
In progress
2016
To develop an in vitro model to recapitulate the human osteoarthritic joint that will provide a device based on a human tissue or a multiple human cell type co-culture system for research and drug development...
In progress
2015
To develop in vitro / in silico assay(s) that can be used singly or in combination to improve risk assessment for GT products. These assays should be applicable to the assessment of a wide range of vector...
In progress
2015
To establish, both qualitatively (which metabolites are produced) and quantitatively (concentration of the metabolites produced), the extent to which skin metabolism determines xenobiotic availability in...
Complete
2014
To use existing toxicological data repositories to develop in silico tools which can be used to predict toxicology endpoints for substances of interest in order to waive in vivo studies.

Pages